Literature DB >> 29059250

Causative species of nontuberculous mycobacterial lung disease and comparative investigation on clinical features of Mycobacterium abscessus complex disease: A retrospective analysis for two major hospitals in a subtropical region of Japan.

Hiroaki Nagano1, Takeshi Kinjo2, Yuichiro Nei1, Shin Yamashiro1, Jiro Fujita2, Tomoo Kishaba1.   

Abstract

Nontuberculous mycobacteria (NTM) lung disease is increasing globally. Although the etiological epidemiology of NTM is different across regions, Mycobacterium avium complex (MAC) is the leading cause of NTM lung disease in most countries, including mainland Japan. Okinawa is located in the southernmost region of Japan and is the only prefecture categorized as a subtropical region in Japan, it is therefore likely the etiological epidemiology of NTM lung disease is different from mainland Japan. From 2009 to 2015, the medical records of patients, with respiratory specimens positive for NTMs, visiting or admitted to two Okinawan hospitals, were retrospectively analyzed. NTM lung disease cases were defined according to the American Thoracic Society criteria and patient epidemiology and clinical information were evaluated. Results indicate four hundred sixteen patients had bacterial cultures positive for NTM. The most common NTM was M. abscessus complex (MABC) (n = 127; 30.5%), followed by M. intracellulare (n = 85; 20.4%). NTM lung disease was diagnosed in 114 patients. Of these cases, MABC was most common (n = 41; 36.0%), followed by M. intracellulare (n = 31; 27.2%). Chronic obstructive pulmonary disease (COPD) and tracheostomy patients were more likely to develop MABC than MAC lung disease. Multivariate analysis showed a probable association between COPD and MABC lung disease. Chest computed tomography (CT) evaluation revealed bronchiectasis, nodules, and consolidation were less frequently observed in MABC patients compared with MAC patients. Our data suggests Okinawa may be one of the few places where MABC is the predominant pathogen causing NTM lung disease and our results add new insight to MABC lung disease, which is not yet well understood.

Entities:  

Mesh:

Year:  2017        PMID: 29059250      PMCID: PMC5653325          DOI: 10.1371/journal.pone.0186826

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Nontuberculous mycobacteria (NTM) are ubiquitous bacteria widely distributed in the environment. NTM can cause a variety of infectious diseases in humans and NTM-induced lung infection is increasing globally [1, 2]. A recently published article shows that the incidence of pulmonary NTM disease in Japan has increased dramatically and cases of pulmonary M. avium complex (MAC), M. kansasii, and M. abscessus complex (MABC) disease were 13.1, 0.6, and 0.5 cases per 100,000 person-years, respectively [3]. The NTM species isolated from patients with NTM lung disease are geographically diverse, nevertheless MAC is the most common species in most countries [4]. Although rapidly growing mycobacteria (RGM), represented by MABC, M. fortuitum, and M. chelonae, are not common pathogens of NTM lung disease, MABC was frequently isolated from NTM lung disease patients in South Korea and Taiwan [3-6]. A single-center study reported from Taiwan, located 500 km south of Okinawa and also categorized as a subtropical region, showed that MABC was the most common species (44.8%) followed by M. fortuitum (23.9%) isolated from NTM lung disease patients; thus, RGM accounted for approximately 70% of the caseload [6]. Because of the subtropical climate of Okinawa is different than that of mainland Japan and is more similar to Taiwan, we hypothesized that the isolation rate for certain causative species of NTM lung disease in Okinawa and mainland Japan is also different. In this study, we retrospectively investigated the causative species of NTM lung disease and the clinical features of MABC induced lung disease, in two representative hospitals from Okinawa.

Materials and methods

Data collection

Between January 2009 and December 2015, patients, with NTMs cultured from respiratory specimens, visiting the outpatient department or admitted to the ward in the Okinawa Chubu Hospital (550 hospital beds) or the University of the Ryukyu Hospital (600 hospital beds), had their medical records retrospectively reviewed. NTM lung disease cases, defined according to the American Thoracic Society (ATS) criteria [7], were identified, underwent etiological analysis by species, and had other clinical information extracted. The clinical background, symptoms, and chest computed tomography (CT) findings of MABC and MAC infected patients were also compared.

Identification of NTM

Respiratory specimens were cultured with 2% Ogawa agar and the resulting bacterial colonies were collected for species identification. The resulting suspension liquid was tested using a DNA-DNA hybridization method from a commercially available identification kit (KYOKUTO Pharmaceutical Industrial Co. Ltd., Tokyo, Japan).

Evaluation of chest CT

Chest CT was evaluated by two experienced chest physicians. Abnormal findings were categorized into; (1) bronchiectasis, (2) nodules, (3) consolidation, (4) cavity, (5) ground-glass opacity, and (6) linear scarring, according to previous reports [8, 9]. Patients could be categorized with more than one finding.

Statistical analysis

Differences among patients’ background, symptoms, and chest CT images were compared for MABC and MAC patients by Fisher’s exact test. The difference in age between these two groups was analyzed by Wilcoxon/Kruskal-Wallis test. A two-sided p-value of <0.05 was considered to be statistically significant. Previously reported risk factors [10-12] for the development of NTM lung disease and possible risk factors revealed by this study were evaluated using logistic regression. All data were analyzed with JMP ver.12 (SAS Institute Inc., North Carolina, USA).

Ethics

The Institutional Ethics Committees of the Okinawa Chubu Hospital and the University of the Ryukyus approved this study.

Results

Pathogen distribution

Four hundred sixteen patients were found with positive NTM culture results from respiratory specimens. As shown in Fig 1, the most frequently detected NTM was MABC (n = 127; 30.5%), followed by M. intracellulare (n = 85; 20.4%). NTM lung disease was diagnosed, according to the ATS criteria, in 114/416 patients (27%). Fig 2 shows the etiology of NTM lung disease patients. Again, the most frequently detected pathogen was MABC (n = 41; 36.0%), followed by M. intracellulare (n = 31; 27.2%).
Fig 1

NTMs cultured from respiratory samples (N = 416).

NTMs isolated from respiratory specimens were retrospectively analyzed. Others category includes: Mycobacterium kansasii (1.0%), M. szulgai (0.7%), M. xenopi (0.7%), M. peregrium (0.5%), M. scrofulaceum (0.5%), M. simiae (0.2%), and M. terrae (0.2%).

Fig 2

Epidemiology of NTM lung disease (N = 114).

NTM lung disease cases, defined according to the American Thoracic Society criteria, were extracted from NTM detected cases shown in Fig 1. Others category includes: Mycobacterium kansasii (0.9%), M. scrofulaceum (0.9%), M. szulgai (0.9%), M. terrae (0.9%), and M. xenopi (0.9%).

NTMs cultured from respiratory samples (N = 416).

NTMs isolated from respiratory specimens were retrospectively analyzed. Others category includes: Mycobacterium kansasii (1.0%), M. szulgai (0.7%), M. xenopi (0.7%), M. peregrium (0.5%), M. scrofulaceum (0.5%), M. simiae (0.2%), and M. terrae (0.2%).

Epidemiology of NTM lung disease (N = 114).

NTM lung disease cases, defined according to the American Thoracic Society criteria, were extracted from NTM detected cases shown in Fig 1. Others category includes: Mycobacterium kansasii (0.9%), M. scrofulaceum (0.9%), M. szulgai (0.9%), M. terrae (0.9%), and M. xenopi (0.9%).

Characteristics of NTM lung disease patients

Clinical background and symptoms were compared for patients diagnosed with either MABC or MAC (n = 41 and 38, respectively). No statistical differences in clinical background, except chronic obstructive pulmonary disease (COPD), tracheotomy, and cerebrovascular disease, were calculated between two groups (Table 1). COPD was more frequent in MABC patients compared with MAC patients (MABC 24% vs MAC 5%, p = 0.0265). Eight tracheotomized patients were included among NTM lung disease patients and all cases were infected with RGM; six of these cases were infected with MABC (MABC 15% vs MAC 0%, p = 0.0261), the remaining two were determined to be M. chelonae. These eight instances of tracheotomy were due to amyotrophic lateral sclerosis (n = 3), disturbed consciousness after operation (n = 1), old healed tuberculosis (n = 1), right lung hypoplasia (n = 1), post-operation of hypopharyngeal cancer (n = 1), symptomatic epilepsy after cerebral infarction (n = 1). Multivariate analysis using logistic regression determined patients with COPD were significantly more likely to develop MABC (Table 2). Observed symptoms were not found to be different between the two groups (Table 3).
Table 1

Patient background.

MABCMAC
[N = 41][N = 38]p value
Age (median)7478.50.0567
Sex (male)17 (41%)12 (32%)0.4840
Smoking history*17 (41%)14 (37%)1.0000
Long-term care facility6 (15%)8 (21%)0.5600
COPD10 (24%)2 (5%)0.0265§
Bronchial asthma7 (17%)3 (8%)0.3145
Old healed tuberculosis7 (17%)6 (16%)1.0000
Bronchiectasis6 (15%)4 (11%)0.7389
Interstitial lung disease2 (5%)3 (8%)0.6675
Thoracic surgery3 (7%)3 (8%)1.0000
Tracheostomy6 (15%)00.0261§
Ventilator2 (5%)1 (3%)1.0000
Tracheal cannulation**6 (15%)1 (3%)0.1101
Gastroesophageal disease4 (10%)3 (8%)1.0000
Lung cancer1 (2%)01.0000
Other solid cancer5 (12%)4 (11%)1.0000
Hematological cancer1 (2%)01.0000
Cardiovascular disease16 (39%)9 (24%)0.1564
Chronic liver disease4 (10%)3 (8%)1.0000
Chronic kidney disease7 (17%)6 (16%)1.0000
Neuromuscular disease3 (7%)5 (13%)0.4711
Cerebrovascular disease2 (5%)9 (24%)0.0221§
Autoimmune disease4 (10%)8 (21%)0.2148
Diabetes mellitus6 (15%)4 (11%)0.7389
HTLV-1*5 (12%)1 (3%)0.1409
Corticosteroid#9 (22%)8 (21%)1.0000
Immunosuppressant5 (12%)2 (5%)0.4338
Acid suppressant23 (56%)16 (42%)0.2629

*Only 76 and 19 patients had data included for smoking history and HTLV-1, respectively.

Patients admitted from long-term care facilities.

**Tracheal cannulation: includes tracheotomized patients and orally intubated patients.

Patients receiving daily corticosteroid at any dose.

Considered significant.

Abbreviations: MABC; Mycobacterium abscessus complex, MAC; Mycobacterium avium complex, COPD; chronic obstructive pulmonary disease, HTLV-1; human T-lymphotropic virus 1

Table 2

Multivariate analysis to determine clinical charecteristics for MABC.

Odds ratio95% CIp value
COPD6.731.31–34.640.0225*
Tracheal cannulation**6.450.69–60.440.1025
Bronchiectasis1.560.36–6.710.5474
Gastroesophageal disease1.230.22–6.960.8157
Old healed tuberculosis0.910.24–3.440.8854

*Considered significant.

**Tracheal cannulation: includes tracheotomized patients and orally intubated patients.

Abbreviations: COPD; chronic obstructive pulmonary disease, CI; confidence interval

Table 3

Symptoms.

MABCMAC
[N = 41][N = 38]p value
Fever (≧38°C)9 (22%)9 (24%)1.0000
Cough16 (39%)18 (47%)0.5009
Sputum31 (76%)27 (71%)0.7995
Hemosputum4 (10%)5 (13%)0.7312
Weight loss*2 (5%)00.4943

*Weight loss was defined as decrease of more than 5% of body weight in 6 months.

Abbreviations: MABC; Mycobacterium abscessus complex, MAC; Mycobacterium avium complex

*Only 76 and 19 patients had data included for smoking history and HTLV-1, respectively. Patients admitted from long-term care facilities. **Tracheal cannulation: includes tracheotomized patients and orally intubated patients. Patients receiving daily corticosteroid at any dose. Considered significant. Abbreviations: MABC; Mycobacterium abscessus complex, MAC; Mycobacterium avium complex, COPD; chronic obstructive pulmonary disease, HTLV-1; human T-lymphotropic virus 1 *Considered significant. **Tracheal cannulation: includes tracheotomized patients and orally intubated patients. Abbreviations: COPD; chronic obstructive pulmonary disease, CI; confidence interval *Weight loss was defined as decrease of more than 5% of body weight in 6 months. Abbreviations: MABC; Mycobacterium abscessus complex, MAC; Mycobacterium avium complex

Chest CT findings

Chest CT was performed for 40 MABC and 36 MAC patients. Bronchiectasis, nodules, and consolidation were observed less frequently in MABC patients compared with MAC patients (Table 4).
Table 4

Chest CT findings.

MABCMAC
[N = 40][N = 36]p value
Bronchiectasis21 (53%)29 (81%)0.0150*
Nodules14 (35%)25 (69%)0.0032*
Consolidation17 (43%)25 (69%)0.0224*
Cavity2 (5%)3 (8%)0.6631
Ground-glass opacity9 (23%)7 (19%)0.7851
Linear scarring30 (75%)26 (72%)0.8003

In total, 67 patients had more than one finding.

*Considered significant.

Abbreviations: MABC; Mycobacterium abscessus complex, MAC; Mycobacterium avium complex

In total, 67 patients had more than one finding. *Considered significant. Abbreviations: MABC; Mycobacterium abscessus complex, MAC; Mycobacterium avium complex

Discussion

MABC was revealed to be the most common causative pathogen for NTM lung disease in this cohort. However, since only two hospitals were involved in the current study, our data may not precisely reveal the etiology of NTM lung disease in Okinawa Prefecture due to sampling bias. However, our data indicates the detection rate of MABC among NTM lung disease patients in Okinawa was altogether different from previous Japanese reports. Morimoto et al., reported the epidemiology of NTM in Japan based on a laboratory-based analysis [13]. Although the data for Okinawa Prefecture was not isolated, MABC was detected more frequently in the Kyushu-Okinawa region than in other, more temperate, regions of Japan. Morimoto et al., also reports that MAC was the most common pathogen to cause NTM lung disease in the Kyushu-Okinawa region [10]. This result is markedly different from our data. For convenience, Okinawa is frequently combined with Kyushu as the "Kyushu-Okinawa region," despite Okinawa being 700 kilometers away from the Kyushu district and falling within the subtropical zone. Due to the climate change and other potential factors, Okinawa experiences unique epidemiological events for many infectious diseases, which can be completely different from those experienced on mainland Japan [14-17]. Additionally, the population of Okinawa is only one tenth the size of Kyushu's (1.4 million vs 13 million). Therefore, we can assume that Okinawa’s distinctive epidemiology, observed in our study, was diminished in the aforementioned article. Moreover, the relatively high isolation rate of MABC in our study is similar to the epidemiology seen in other Asian countries [4, 5]. In Taiwan and South Korea, the isolation rate of MABC from NTM lung disease patients is higher [6, 18–21]. Frequently, differences in epidemiology can be explained by differences in climate conditions, environmental exposure, ethnic backgrounds, and laboratory practices (i.e., culture temperatures) [5]. The climate conditions of Okinawa and Taiwan are both classified as subtropical, however climate conditions in South Korea are decidedly different. Although further research is needed, common factors among South Korea, Taiwan, and Okinawa may be able to explain this characteristic epidemiology. Our multivariate analysis showed a possible association between COPD and MABC infection. COPD was previously reported as a risk factor for NTM lung disease, however the distinct species, associated with COPD patients, was not specified [22]. As far as we know, risk factors related to the development of MABC lung disease remain unclear. However, past studies revealed that cystic fibrosis, gastroesophageal disease, and previous mycobacterial lung disease should be considered as potential risk factors related to the development of RGM induced lung disease [23, 24]. Since RGM induced lung disease is predominantly due to MABC [25], the risk factors mentioned above should also be considered risk factors for MABC lung disease. As with cystic fibrosis and previous mycobacterial lung disease, normal lung structure is destroyed and clearance of sputum is impaired in COPD, thus it is likely that COPD patients are susceptible to MABC infection, as also described by Chan et al. [26]. Since tracheostomy was not an appropriate variable for logistic regression in this study because of no tracheotomized patient in MAC group, tracheal cannulation was evaluated by multivariate analysis. Although the relationship between MABC and tracheal cannulation was not determined to be statistically significant, it is noteworthy that all tracheotomized patients with NTM lung disease had cultures positive for RGM (MABC: 6 cases, M. chelonae: 2 cases) in our study. Although information regarding the relationship between tracheotomy and MABC is limited, Do et al., reported that MABC was frequently detected from children with tracheostomy [27]. Their study retrospectively reviewed 5-years of data on MABC infection in a pediatric pulmonary center and 16 cases infected with MABC were identified. Of these, medical records were available for 15 patients and 73% of cases (11/15) were patients with tracheostomy. Lee et al., also showed MABC was frequently identified among ventilator-dependent patients [28]. Since RGM including MABC can cause skin and soft tissue colonization and infection, we speculate that MABC infection around tracheostomy may traverse the tracheal epithelium and eventually cause lung infection. There is limited data concerning the clinical manifestations of MABC lung disease. Griffith et al., reported that cough was the most frequent symptom (70%) in RGM patients and hemoptysis and dyspnea were also common [25]. However, there are no RGM-specific respiratory symptoms, and our results also confirm this. Our study demonstrated that bronchiectasis, nodules, and consolidation were observed more frequently in MAC patients than in MABC patients. According to Chung et al., no significant difference was observed in the presence of small nodules, tree-in-bud pattern, and bronchiectasis between two groups [29]. However, nodule, airspace consolidation, and thin-walled cavities were observed more frequently in MAC patients. Thus, results regarding bronchiectasis and cavitation were different from our study. Although the precise reason is unknown, one possible explanation is the difference of patients’ background. There are two major radiographic features of NTM lung disease; fibrocavitary form and nodular bronchiectatic form, with the former pattern often seen in older male patients with underlying lung disease such as COPD [7, 10]. Since COPD was more frequent in MABC patients compared with MAC patients in our study, bronchiectasis and nodules may be observed less frequently in MABC group. Another explanation for the differing radiographic findings may be the multiple subspecies of MABC. It has been reported that the etiological epidemiology of three subspecies of MABC (M. abscessus, M. massiliense, and M. bolletii) varies due to geographical region. Furthermore, differences in the genotypes of M. abscessus and M. massiliense were associated with varying radiological features and abnormal shadows in the lung [30, 31]. Since the distributional pattern of MABC genotypes is assumed different between Okinawa and South Korea, it is possible that the radiological features of MABC lung disease are also different. Our study has some limitations. As a retrospective study conducted in two hospitals, our data is sparse and potentially biased. Data from several more hospitals in Okinawa should be collected to reveal a more accurate epidemiology of NTM lung disease in Okinawa. Additionally, we did not identify MABC to the subspecies level. According to DNA sequence and drug sensitivity, MABC is divided into 3 subspecies: M. abscessus (A-type), M. massiliense (M-type), and M. bolletii (B-type) [32-Annals of the American Thoracic Society. 2015 ">35]. Because some studies have shown differences among the biological characteristics, antibiotic sensitivity, and clinical features of the three subspecies of MABC [36, 37], differentiation of three subspecies of MABC may reveal more profound results. Nevertheless, if treated as a pilot study, our results revealed considerable differences regarding the epidemiology of NTM lung disease in Okinawa, Japan and provided valuable insight regarding the differences between the clinical characteristics of MABC and MAC lung disease. Further studies are needed to present a more accurate understanding of the epidemiology, clinical features, and risk factors of MABC lung disease.

Data for figures and tables.

[Raw data for 2nd submission.xlsx]. (XLSX) Click here for additional data file.
  37 in total

1.  Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea.

Authors:  Y S Park; C-H Lee; S-M Lee; S-C Yang; C-G Yoo; Y W Kim; S K Han; Y-S Shim; J-J Yim
Journal:  Int J Tuberc Lung Dis       Date:  2010-08       Impact factor: 2.373

2.  Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy.

Authors:  Hyun Su Kim; Kyung Soo Lee; Won-Jung Koh; Kyeongman Jeon; Eun Ju Lee; Hee Kang; Joonghyun Ahn
Journal:  Radiology       Date:  2012-02-27       Impact factor: 11.105

3.  Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis.

Authors:  A Telenti; F Marchesi; M Balz; F Bally; E C Böttger; T Bodmer
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

4.  Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus.

Authors:  Won-Jung Koh; Kyeongman Jeon; Nam Yong Lee; Bum-Joon Kim; Yoon-Hoh Kook; Seung-Heon Lee; Young Kil Park; Chang Ki Kim; Sung Jae Shin; Gwen A Huitt; Charles L Daley; O Jung Kwon
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

Review 5.  Strongyloidiasis--progress in diagnosis and treatment.

Authors:  O Zaha; T Hirata; F Kinjo; A Saito
Journal:  Intern Med       Date:  2000-09       Impact factor: 1.271

Review 6.  Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease.

Authors:  Edward D Chan; Xiyuan Bai; Marinka Kartalija; Ian M Orme; Diane J Ordway
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-15       Impact factor: 6.914

7.  Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases.

Authors:  Toshiyuki Harada; Yasushi Akiyama; Atsuyuki Kurashima; Hideaki Nagai; Kazunari Tsuyuguchi; Takashi Fujii; Syuichi Yano; Eriko Shigeto; Toshihiko Kuraoka; Akira Kajiki; Yoshihiro Kobashi; Fumio Kokubu; Atsuo Sato; Shiomi Yoshida; Tomotada Iwamoto; Hajime Saito
Journal:  J Clin Microbiol       Date:  2012-08-22       Impact factor: 5.948

8.  Clinical significance of respiratory isolates for Mycobacterium abscessus complex from pediatric patients.

Authors:  Paul C M Do; Eliezer Nussbaum; John Moua; Terry Chin; Inderpal Randhawa
Journal:  Pediatr Pulmonol       Date:  2012-07-25

9.  Mycobacterial genotypes are associated with clinical manifestation and progression of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense.

Authors:  Sung Jae Shin; Go-Eun Choi; Sang-Nae Cho; Sook Young Woo; Byeong-Ho Jeong; Kyeongman Jeon; Won-Jung Koh
Journal:  Clin Infect Dis       Date:  2013-03-19       Impact factor: 9.079

Review 10.  Nontuberculous mycobacteria in respiratory tract infections, eastern Asia.

Authors:  Sami Simons; Jakko van Ingen; Po-Ren Hsueh; Nguyen Van Hung; P N Richard Dekhuijzen; Martin J Boeree; Dick van Soolingen
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

View more
  11 in total

1.  In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus.

Authors:  Eva Le Run; Michel Arthur; Jean-Luc Mainardi
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research.

Authors:  Shelby Daniel-Wayman; Getahun Abate; Daniel L Barber; Luiz E Bermudez; Rhea N Coler; Michael H Cynamon; Charles L Daley; Rebecca M Davidson; Thomas Dick; R Andres Floto; Emily Henkle; Steven M Holland; Mary Jackson; Richard E Lee; Eric L Nuermberger; Kenneth N Olivier; Diane J Ordway; D Rebecca Prevots; James C Sacchettini; Max Salfinger; Christopher M Sassetti; Christine F Sizemore; Kevin L Winthrop; Adrian M Zelazny
Journal:  Am J Respir Crit Care Med       Date:  2019-04-15       Impact factor: 21.405

3.  THP-1 and Dictyostelium Infection Models for Screening and Characterization of Anti-Mycobacterium abscessus Hit Compounds.

Authors:  Adrian Richter; Tirosh Shapira; Yossef Av-Gay
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

4.  Single Cell Analysis of Drug Susceptibility of Mycobacterium Abscessus During Macrophage Infection.

Authors:  Joanna Brzostek; Amierah Fatin; Wen Hui Chua; Hui Yi Tan; Thomas Dick; Nicholas R J Gascoigne
Journal:  Antibiotics (Basel)       Date:  2020-10-17

Review 5.  Mycobacterium abscessus: Shapeshifter of the Mycobacterial World.

Authors:  Keenan Ryan; Thomas F Byrd
Journal:  Front Microbiol       Date:  2018-11-01       Impact factor: 5.640

6.  Longitudinal non-cystic fibrosis trends of pulmonary Mycobacterium abscessus disease from 2010 to 2017: spread of the "globally successful clone" in Asia.

Authors:  Aristine Cheng; Hsin-Yun Sun; Yi-Tzu Tsai; Po-Liang Lu; Susan Shin-Jung Lee; Yi-Tzu Lee; Yung-Chih Wang; Po-Yu Liu; Jung-Yien Chien; Po-Ren Hsueh; Shu-Yuan Chang; Un-In Wu; Wang-Huei Sheng; Yee-Chun Chen; Shan-Chwen Chang
Journal:  ERJ Open Res       Date:  2021-01-18

7.  Species identification and antimicrobial susceptibility testing of non-tuberculous mycobacteria isolated in Chongqing, Southwest China.

Authors:  Huizheng Zhang; Ming Luo; Ke Zhang; Xin Yang; Kui Hu; Zongqiang Fu; Liwen Zhang; Ping Wu; Dongyong Wan; Mei Han; Xiaoying Wang
Journal:  Epidemiol Infect       Date:  2020-12-28       Impact factor: 2.451

8.  Radiological findings in nontuberculous mycobacterial pulmonary diseases: A comparison between the Mycobacterium avium complex and the Mycobacterium abscessus complex.

Authors:  Hiroaki Nagano; Takeshi Kinjo; Jiro Fujita; Tomoo Kishaba
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

Review 9.  Pulmonary Mycobacterium abscessus Infection with Reactive AA Amyloidosis: A Case Report and Brief Review of the Literature.

Authors:  Ryo Torii; Shingo Noguchi; Ikuko Shimabukuro; Yuri Inokuchi; Akinari Tabaru; Chiharu Yoshii; Kazuhiro Yatera
Journal:  Intern Med       Date:  2018-10-17       Impact factor: 1.271

10.  Thiostrepton: A Novel Therapeutic Drug Candidate for Mycobacterium abscessus Infection.

Authors:  Tae Ho Kim; Bui Thi Bich Hanh; Guehye Kim; Da-Gyum Lee; June-Woo Park; So Eui Lee; Jae-Sung Kim; Byoung Soo Kim; Sungweon Ryoo; Eun-Kyeong Jo; Jichan Jang
Journal:  Molecules       Date:  2019-12-10       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.